Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 12, 2005, Pages 1384-1391

  Hicks, Rodney J ^a,b   Rischin, Danny ^a,b   Fisher, Richard ^a   Binns, David ^a   Scott, Andrew M ^c   Peters, Lester J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

Advanced head and neck cancer; Chemoradiotherapy; Hypoxia; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; FLUORODEOXYGLUCOSE F 18; TIRAPAZAMINE; TRACER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG TARGETING; DRUG UPTAKE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOXIA; LUNG CANCER; LYMPH NODE METASTASIS; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; QUALITATIVE ANALYSIS; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SURVIVAL RATE; TARGET CELL DESTRUCTION; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZYLAMINES; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COHORT STUDIES; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION-SENSITIZING AGENTS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TRIAZINES;

EID: 28544444512     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1880-2     Document Type: Article

References (20)

1. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-55
2. Gray LH, Conger AD, Ebert M, Hornesy S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48
3. Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-8
4. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-9
5. Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57:39-43
6. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9
7. Brown JM. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 1993;67:1163-70
8. Rischin D, Peters L, Hicks R, Hughes P, Fisher R, Hart R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:535-42
9. Brown JM, Lemmon MJ. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 1990;50:7745-9
10. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53:4633-6
11. 137Cs in whole-body PET imaging. J Nucl Med 1999;40:1257-63
12. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47(3):551-60
13. MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-93
14. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61
15. Rasey JS, Martin GV, Krohn KA. Quantifying hypoxia with radiolabeled fluoromisonidazole: pre-clinical and clinical studies. In: Machulla H-J, editor. Imaging of hypoxia. Dordrecht: Kluwer Academic Publishers; 1999. p. 85-117
16. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60
17. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195:1-16
18. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28
19. 18F-misonidazole (FMISO) PET scanning. Proc Am Soc Clin Oncol 2004;23:491
20. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005;46:253-60